Ghent University-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2019

  1. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: Long-term results of the PRIMA study

    Journal of Clinical Oncology, Vol. 37, Núm. 31, pp. 2815-2824

2016

  1. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial

    Journal of Clinical Oncology, Vol. 34, Núm. 22, pp. 2575-2582

2011

  1. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial

    The Lancet, Vol. 377, Núm. 9759, pp. 42-51